The measurement properties of Patient-Reported Outcomes Measurement Information System Global Health in adult patients with atopic dermatitis is examined.
For moderate-to-severe atopic dermatitis, the oral Janus kinase 1 (JAK1) inhibitor abrocitinib at 200 mg or 100 mg once daily results in significantly greater reductions in signs and symptoms versus placebo.
The percentage of positive and relevant allergens in those younger than 18 years with hand eczema referred for patch testing was determined.
A 2-step alkaline care regimen for the treatment of eczema is tested.
The real-world global prevalence of atopic dermatitis in the pediatric population was estimated.
The phenotype characteristics that best describe children flaring during pollen season were investigated.
Patients with mild to moderate atopic dermatitis and comorbid asthma or allergic rhinitis treated with crisaborole had significantly higher treatment success rates compared with vehicle control.
The benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B phototherapy for patients with severe atopic dermatitis was quantified.
Children with atopic dermatitis who were treated with dupilumab and topical corticosteroids showed improvements in treatment success compared with topical corticosteroids alone.
“The diagnosis of disseminated bullous impetigo can be challenging, and initial misdiagnosis is common,” noted the researchers.